Your browser doesn't support javascript.
loading
Cell motility and migration as determinants of stem cell efficacy.
Danielyan, Lusine; Schwab, Matthias; Siegel, Georg; Brawek, Bianca; Garaschuk, Olga; Asavapanumas, Nithi; Buadze, Marine; Lourhmati, Ali; Wendel, Hans-Peter; Avci-Adali, Meltem; Krueger, Marcel A; Calaminus, Carsten; Naumann, Ulrike; Winter, Stefan; Schaeffeler, Elke; Spogis, Annett; Beer-Hammer, Sandra; Neher, Jonas J; Spohn, Gabriele; Kretschmer, Anja; Krämer-Albers, Eva-Maria; Barth, Kerstin; Lee, Hong Jun; Kim, Seung U; Frey, William H; Claussen, Claus D; Hermann, Dirk M; Doeppner, Thorsten R; Seifried, Erhard; Gleiter, Christoph H; Northoff, Hinnak; Schäfer, Richard.
Afiliación
  • Danielyan L; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany; Neuroscience Laboratory and Departments of Biochemistry and Clinical Pharmacology, Yerevan State Medical University, Yerevan, Armenia. Electronic address: lusine.danielyan@med.uni-tuebingen.de.
  • Schwab M; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany; Neuroscience Laboratory and Departments of Biochemistry and Clinical Pharmacology, Yerevan State Medical University, Yerevan, Armenia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germ
  • Siegel G; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Brawek B; Institute of Physiology, Department of Neurophysiology, University of Tübingen, Tübingen, Germany.
  • Garaschuk O; Institute of Physiology, Department of Neurophysiology, University of Tübingen, Tübingen, Germany.
  • Asavapanumas N; Institute of Physiology, Department of Neurophysiology, University of Tübingen, Tübingen, Germany.
  • Buadze M; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
  • Lourhmati A; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
  • Wendel HP; Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Avci-Adali M; Department of Thoracic, Cardiac and Vascular Surgery, University Hospital Tübingen, Tübingen, Germany.
  • Krueger MA; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany.
  • Calaminus C; Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, University Hospital Tübingen, Tübingen, Germany.
  • Naumann U; Hertie Institute for Clinical Brain Research and Center Neurology, Department of Vascular Neurology, Tübingen Neuro-Campus (TNC), University of Tübingen, Tübingen, Germany.
  • Winter S; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany.
  • Schaeffeler E; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany.
  • Spogis A; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
  • Beer-Hammer S; Department of Pharmacology, Experimental Therapy and Toxicology, Institute of Experimental and Clinical Pharmacology and Pharmacogenomic, and ICePhA, University Hospital Tübingen, Tübingen, Germany.
  • Neher JJ; Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; German Center for Neurodegenerative Diseases (DZNE), Tübingen, Tübingen, Germany.
  • Spohn G; Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe-University Hospital, Frankfurt am Main, Germany.
  • Kretschmer A; Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe-University Hospital, Frankfurt am Main, Germany.
  • Krämer-Albers EM; Institute for Developmental Biology and Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Barth K; Institute for Developmental Biology and Neurobiology, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Lee HJ; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea; Research Institute eBiogen Inc., Seoul, Republic of Korea.
  • Kim SU; Division of Neurology, Department of Medicine, UBC Hospital, University of British Columbia, Vancouver, BC, Canada.
  • Frey WH; HealthPartners Center for Memory and Aging, HealthPartners Neurosciences, St. Paul, MN, U.S.A.
  • Claussen CD; Department of Radiology, University Hospital Tübingen, Tübingen, Germany.
  • Hermann DM; Department of Neurology, University of Duisburg-Essen, Essen, Germany.
  • Doeppner TR; Department of Neurology, University of Duisburg-Essen, Essen, Germany; Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
  • Seifried E; Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe-University Hospital, Frankfurt am Main, Germany.
  • Gleiter CH; Department of Clinical Pharmacology, University Hospital Tübingen, Tübingen, Germany.
  • Northoff H; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany.
  • Schäfer R; Institute of Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany; Institute for Transfusion Medicine and Immunohematology, German Red Cross Blood Donor Service Baden-Württemberg-Hessen gGmbH, Goethe-University Hospital, Frankfurt am Main, Germany. Electron
EBioMedicine ; 60: 102989, 2020 Oct.
Article en En | MEDLINE | ID: mdl-32920368
ABSTRACT

BACKGROUND:

Stem cells` (SC) functional heterogeneity and its poorly understood aetiology impedes clinical development of cell-based therapies in regenerative medicine and oncology. Recent studies suggest a strong correlation between the SC migration potential and their therapeutic efficacy in humans. Designating SC migration as a denominator of functional SC heterogeneity, we sought to identify highly migrating subpopulations within different SC classes and evaluate their therapeutic properties in comparison to the parental non-selected cells.

METHODS:

We selected highly migrating subpopulations from mesenchymal and neural SC (sMSC and sNSC), characterized their features including but not limited to migratory potential, trophic factor release and transcriptomic signature. To assess lesion-targeted migration and therapeutic properties of isolated subpopulations in vivo, surgical transplantation and intranasal administration of MSCs in mouse models of glioblastoma and Alzheimer's disease respectively were performed.

FINDINGS:

Comparison of parental non-selected cells with isolated subpopulations revealed superior motility and migratory potential of sMSC and sNSC in vitro. We identified podoplanin as a major regulator of migratory features of sMSC/sNSC. Podoplanin engineering improved oncovirolytic activity of virus-loaded NSC on distantly located glioblastoma cells. Finally, sMSC displayed more targeted migration to the tumour site in a mouse glioblastoma model and remarkably higher potency to reduce pathological hallmarks and memory deficits in transgenic Alzheimer's disease mice.

INTERPRETATION:

Functional heterogeneity of SC is associated with their motility and migration potential which can serve as predictors of SC therapeutic efficacy.

FUNDING:

This work was supported in part by the Robert Bosch Stiftung (Stuttgart, Germany) and by the IZEPHA grant.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Células Madre / Movimiento Celular Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: EBioMedicine Año: 2020 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Células Madre / Movimiento Celular Tipo de estudio: Prognostic_studies Límite: Animals / Humans / Male Idioma: En Revista: EBioMedicine Año: 2020 Tipo del documento: Article